ABVC BioPharma Reveals Receipt Of $200K Cash Payment From OncoX BioPharma As Part Of Its Strategic Licensing Agreement For Certain Oncology-related Products
ABVC BioPharma Reveals Receipt Of $200K Cash Payment From OncoX BioPharma As Part Of Its Strategic Licensing Agreement For Certain Oncology-related Products
ABVC生物制药公司透露，收到OncoX生物制药公司200,000美元的现金付款，作为其某些肿瘤相关产品战略许可协议的一部分。
This payment marks the first installment of $5 million in potential licensing fees from OncoX.
这笔支付标志着从OncoX获得潜在许可费的第一期500万美元。
With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.
通过这笔支付，ABVC从其三家战略合作伙伴那里获得的各种ABVC产品的累计现金支付总额为546,000美元。ABVC及其子公司BioLite Inc.和Rgene Corporation都有资格在产品推出后各自获得最多1000万OncoX股票、500万美元现金支付以及最高5000万美元的特许权使用费。
资讯热榜
更新时间